Journal of
Neuroscience and Behavioral Health

  • Abbreviation: J. Neurosci. Behav. Health
  • Language: English
  • ISSN: 2141-2286
  • DOI: 10.5897/JNBH
  • Start Year: 2009
  • Published Articles: 65

Review

Hormone replacement therapy and Alzheimer's disease in older women: A systematic review of literature

Abdu Wakawa Ibrahim
  • Abdu Wakawa Ibrahim
  • Department of Mental Health, College of Medical Sciences, University of Maiduguri, Maiduguri - Borno State, Nigeria.
  • Google Scholar
Olufunke Adebola Sodipo
  • Olufunke Adebola Sodipo
  • Department of Clinical Pharmacology and Therapeutics, College of Medical Sciences, University of Maiduguri, Maiduguri - Borno state, Nigeria.
  • Google Scholar
Ibrahim Adamu Mshelia
  • Ibrahim Adamu Mshelia
  • Department of Mental Health, Federal Neuropsychiatric Hospital, Maiduguri, Nigeria.
  • Google Scholar
Babagana Kundi Machina
  • Babagana Kundi Machina
  • Department of Psychiatry, Yobe Specialists Hospital, Damaturu - Yobe State, Nigeria.
  • Google Scholar


  •  Received: 17 July 2017
  •  Accepted: 23 April 2018
  •  Published: 30 April 2018

References

Alzheimer's Association (2016). 2016 Alzheimer's disease facts and figures. Alzheimers Dement, 12(4):459-509.
Crossref

 

Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, Dartigues JF, Kragh-Sorensen P, Baldereschi M, Brayne C, Lobo A, Martinez-Lage JM, Stijnen T, Hofman A (1999). Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology 53(9):1992-1997.
Crossref

 
 

Baiyewu O (2003). Dementia in Nigeria. Arch. Ibadan Med. 4(1):21-22.

 
 

Baldereschi M, Di Carlo A, Lepore V, Bracco L, Maggi S, Grigoletto F, Scarlato G, Amaducci L (1998). Estrogen-replacement therapy and Alzheimer's disease in the Italian longitudinal study on aging. Neurology 50(4):996-1002.
Crossref

 
 

Barrett-Connor E, Laughlin GA (2009). Endogenous and exogenous estrogen, cognitive function and dementia in postmenopausal women: evidence from epidemiologic studies and clinical trials. Semin. Reprod. Med. 27(3):275-282.
Crossref

 
 

Behl C, Widmann M, Trapp T, Holsboer F (1995). 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem. Biophys. Res. Commun. 216:473-482.
Crossref

 
 

Bishara D, Sauer J, Taylor D (2015). The pharmacological management of Alzheimer's disease. Prog. Neurol. Psych. 19(4):9-16.
Crossref

 
 

Bishop J, Simpkins JW (1995). Estradiol enhances brain glucose uptake in ovariectomized rats. Brain Res. Bull. 36(3):315-20.
Crossref

 
 

Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C (2012). The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol. Assess. 16(21):1-470.
Crossref

 
 

Brenner DE, Kukull WA, Stergachis A, van Belle G, Bowen JD, McCormick WC, Teri L, Larson EB (1994). Postmenopausal estrogen therapy and the risk of Alzheimer's disease: a population-based case control study. Am. J. Epidemiol. 140(3):262-267.
Crossref

 
 

Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM (2013). Acetylcholinesterase Inhibitors: pharmacology and toxicology. Curr. Neuropharmacol. 11(3):315-335.
Crossref

 
 

Craig MC, Murphy DGM (2009). Alzheimer's disease in women. Best Pract. Res. Clin. Obstet. Gynaecol. 23(1):53-61. 
Crossref

 
 

De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007). Aβ oligomers induce neuronal oxidative stress through an N-Methyl-D-Aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 282(15):11590-11601.
Crossref

 
 

Dong S, Duan Y, Hu Y, Zhao Z (2012). Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of the amyloid cascade hypothesis. Transl. Neurodegener. 1(1):18.
Crossref

 
 

Epperson CN, Sammel MD, Freeman EW (2013). Menopause effects on verbal memory: findings from a longitudinal community cohort. J. Clin. Endocrinol. Metab. 98(9):3829-3838.
Crossref

 
 

Fillit H, Luinne V (1997). The neurobiology of gonadal hormones and cognitive decline in late life. Maturitas 26(3):159-164.
Crossref

 
 

Fillit HM (2002). The role of hormone replacement therapy in the prevention of Alzheimer disease. Arch. Intern. Med. 162(17):1934-1942.
Crossref

 
 

Gabelli C, Codemo A (2015). Gender differences in cognitive decline and Alzheimer's disease. Ital. J. Gender-Specific Med. 1:21-28.

 
 

Gao S, Hendrie HC, Hall KS, Hui S (1998). The relationship between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch. Gen. Psychol. 55:809-815.
Crossref

 
 

Gazzaley AH, Weiland NG, McEwen BS, Morrison JH (1996). Differential regulation of NMDAR1 mRNA and protein by estradiol in the rat hippocampus. J. Neurosci. 16(21):6830-6838.
Crossref

 
 

Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, Brinton EA, Cedars MI, Lobo RA, Merriam GR, Neal-Perry G (2015). Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-cognitive and affective study. PLoS Med. 12(6):e1001833.
Crossref

 
 

Goodman Y, Bruce AJ, Cheng B, Mattson MP (1996). Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J. Neurochem. 66:1836-1844.
Crossref

 
 

Grodstein F (2017). Estrogen and cognitive function. 

 
 

Hall KS, Gao S, Baiyewu O, Lane KA, Gureje O, Shen J, Ogunniyi A, Murrell JR, Unverzagt FW, Dickens J, Smith-Gamble V, Hendrie HC (2009). Prevalence rates for dementia and Alzheimer's disease in African Americans: 1992 versus 2001. Alzheimers Dement. 5(3):227-233.
Crossref

 
 

Hebert LE, Weuve J, Scherr PA, Evans DA (2013). Alzheimer's disease in the United States (2010 - 2050) estimated using the 2010 census. Neurology 80(19):1778-1783.
Crossref

 
 

Henderson VW (1997). Estrogen replacement therapy for the prevention and treatment of Alzheimer's disease. CNS Drugs 8:343-351.
Crossref

 
 

Henderson VW (2008). Cognitive changes after menopause: influence of estrogen. Clin. Obst. Gynecol. 51(3):618-626.
Crossref

 
 

Henderson VW (2014). Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause. J. Steroid Biochem. Mol. Biol. 142:99-106.
Crossref

 
 

Henderson VW, St John JA, Hodis HN, Kono N, McCleary CA, Franke AA, Mack WJ (2012). WISH research group, Long-term soy isoflavone supplementation and cognition in women: a randomized. controlled trial. Neurology 78(23):1841-1848.
Crossref

 
 

Henderson VW, St John JA, Hodis HN, McCleary CA, Stanczyk FZ, Shoupe D, Kono N, Dustin L, Allayee H, Mack WJ (2016). Cognitive effects of estradiol after menopause: a randomized trial of timing hypothesis. Neurology 87(7):699-708.
Crossref

 
 

Henderson W, Benke KS, Green RC, Cupples LA, Farrer LA (2005). Postmenopausal hormone therapy and the Alzheimer's disease risk: interaction with age. J. Neurol. Neurosurg. Psych. 76:103-105.
Crossref

 
 

Higgins JPT, Green S (2011). Cochrane Handbook for Systematic Review of Interventions Version 5.1.0. 

 
 

Hogan DB (2014). Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer's disease. Can. J. Psychiatry 59(12):618-623.
Crossref

 
 

Hogervorst E, Williams J, Budge M, Riedel W, Jolles J (2000). The nature of the effect of female gonadal hormone replacement therapy on cognitive function in postmenopausal women: a meta-analysis. Neuroscience 101(3):485-512.
Crossref

 
 

Honq-Qi Y, Zhi-Kun S, Sheng-Di C (2012). Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and Tau. Transl. Neurodegener. 1(1):21.
Crossref

 
 

Imtiaz B, Taipale H, Tanskanen A, Tiihonen M, Kivipelto M, Heikkinen AM (2017). Risk of Alzheimer's disease among users of postmenopausal hormone therapy: a nation-wide case-control study. Maturitas 98:7-13.
Crossref

 
 

Imtiaz B, Tuppurainen M, Rikkonen T, Kivipelto M, Soininen H, Krogger H (2017). Postmenopausal hormone therapy and Alzheimer's disease. Neurology 88(11):1062-1068.
Crossref

 
 

Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE (1994). Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J. Biol. Chem. 269:13065-13068.

 
 

Jamshed N, Ozair FF, Aggarwal P, Ekka M (2014). Alzheimer's disease in postmenopausal women: intervene in the critical window period. J. Midlife Health 5(1):38-40.
Crossref

 
 

Janicki SC, Schupf N (2010). Hormonal influences on cognition and risk for Alzheimer's disease. Curr. Neurol. Neurosci. Rep. 10(5):359-366.
Crossref

 
 

Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle DD, Metter E (1997). A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study of aging. Neurology 46:1517-1521.
Crossref

 
 

Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA (1998). Interactions of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139(10):4252-4263.
Crossref

 
 

Lakhan SE, Caro M, Hadzimichalis N (2013). NMDA Receptor Activity in Neuropsychiatric Disorders. Front Psychiatry 4:52.
Crossref

 
 

LeBlanc ES, Janowsky J, Chan BK, Nelson HD (2001). Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 285(11):1489-1499.
Crossref

 
 

Liang K, Yang L, Yin C, Xiao Z, Zhang J, Liu Y, Huang J (2010). Estrogen stimulates degradation of β - amyloid peptide by upgrading neprilysin. J. Biol. Chem. 285:935-942.
Crossref

 
 

Luine VN (1985). Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp. Neurol. 89(2):484-490.
Crossref

 
 

Maki PM, Henderson VW (2012). Hormone therapy, dementia, and cognition: The Women's Health Initiatives Ten Years On. Climacteric 15(3):256-262.
Crossref

 
 

Maki PM, Resnick SM (2000). Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol. Aging 21(2):373-383.
Crossref

 
 

McCarrey AC, Resnick SM (2015). Postmenopausal hormone therapy and cognition. Horm. Behav. 74:167-172.
Crossref

 
 

McEwen BS (1999). The molecular and neuroanatomical basis for estrogen effects in the central nervous system. J. Clin. Endocrin. Metab. 84:1790.
Crossref

 
 

Mehta M, Adem A, Sabbagh M (2012). New Acetylcholinesterase inhibitors for Alzheimer's disease. Int. J. Alzheimers Dis. 2012:728983.
Crossref

 
 

Mielke MM, Vemuri P, Rocca WA (2014). Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin. Epidemiol. 6:37-48.
Crossref

 
 

Molsa PK, Martila RJ, Rinne UK (1982). Epidemiology of dementia in Finnish population. Act. Neurol. Scand. 65:541-552.
Crossref

 
 

Morley BJ, Rodriguez-Sierra JF, Clough RW (1983). Increase in hypothalamic nicotinic acetylcholine receptors in prepuberal female rats administered estrogen. Brain Res. 278(1-2):262-265.
Crossref

 
 

Ohkura T, Teshima Y, Isse K, Matsuda H, Inoue T, Sakai Y, Iwasaki N, Yaoi Y (1995). Estrogen increases cerebral and cerebellar blood flows in post-menopausal women. Menopause 2(1):13-18.
Crossref

 
 

Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, Huang X (2012). N-Methyl-D-Aspartate (NMDA) antagonists and memantine treatment for Alzheimer's disease, vascular dementia, and Parkinson's disease. Curr. Alzheimer Res. 9(6):746-758.
Crossref

 
 

Paganini-Hill A, Clark LJ (2000). Preliminary assessment of cognitive functions in breast cancer patients treated with Tamoxifen. Breast Cancer Res. Treat. 64(2):165-176.
Crossref

 
 

Paganini-Hill A, Henderson VW (1994). Estrogen deficiency and risk of Alzheimer's disease in women. Am. J. Epidemiol. 140:256-261.
Crossref

 
 

Paganini-Hill A, Henderson W (1996). Estrogen replacement therapy and risk of Alzheimer's disease. Arch. Intern. Med. 156:2213-2217.
Crossref

 
 

Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC (2007). Prevalence of dementia in the US: the aging, demographics, and memory study. Neuroepidemiology 29(1-2):125-132.
Crossref

 
 

Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D (2003). Effect of estrogen plus progestin on global cognitive function in postmenopausal women the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289(20):2663-2672.
Crossref

 
 

Resnick SM, Maki PM, Golski S, Kraut MA, Zonderman AB (1998). Effects of estrogen replacement therapy on PET cerebral blood flow and cognition and neuropsychological performance. Horm. Behav. 34(2):171-182.
Crossref

 
 

Roberts RO, Cha RH, Knopman DS, Petersen RC, Rocca WA (2006). Postmenopausal estrogen therapy and Alzheimer's disease: overall negative findings. Alzheimer Dis. Assoc. Disord. 20(3):141-146.
Crossref

 
 

Seshadri S, Zomberg GL, Derby LE, Myers MW, Jick H, Drachman DA (2001). Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease. Arch. Neurol. 58:435-440.
Crossref

 
 

Shao H, Breitner JC, Whitmer RA, Wang J, Hayden K, Wengreen H, Corcoran C, Tschanz J, Norton M, Munger R, Welsh-Bohmer K, Zandi PP (2012). Hormone therapy and Alzheimer's dementia disease: new findings from the Cache County Study. Neurology 79(18):1846-1852.
Crossref

 
 

Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH (2004). Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291(24):2947-2958.
Crossref

 
 

Shumaker SA1, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study (WHIMS). JAMA 289(20):2651-2662.
Crossref

 
 

Slooter AJ, Bronzova J, Witteman JC, Van Broeckhoven C, Hofman A, van Duijn CM (1999). Estrogen use and early-onset Alzheimer's disease: a population-based study. J. Neurosurg. Psychol. 67(6):779-781.
Crossref

 
 

Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R (1996). Effects of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348:429-432.
Crossref

 
 

Toran-Allerand CD, Miranda RC, Bentham WD, Bentham WDL, Sohrabji F, Brown TJ, Hochberg RB, MacLusky NJ (1992). Estrogen receptors co-localize with low affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc. Natl. Acad. Sci. 89:4668-4672.
Crossref

 
 

Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E (1999). Postmenopausal estrogen replacement therapy and risk of Alzheimer's disease: a population-based study. Neurology 52:965-970.
Crossref

 
 

Wenk GL, Parsons CG, Danysz W (2006). Potential role of N-Methyl-D-Aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav. Pharmacol. 17:411-424.
Crossref

 
 

White LR, Petrovitch H, Ross GW, Masaki K, Hardman J, Nelson J, Davis D, Markesbery W (2000). Brain aging and midlife tofu consumption. J. Am. Coll. Nutr. 19:242-255.
Crossref

 
 

World Alzheimer Report (2015). The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. 

 
 

Xiao ZM, Sun L, Liu YM, Zhang JJ, Huang J (2009). Estrogen regulation of neprilysin gene through a hormone-responsive element. J. Mol. Neurosci. 39:22-26.
Crossref

 
 

Yaffe K, Krueger K, Sarkar S, Grady D, Barrett-Connor E, Cox DA, Nickelsen T (2001). Cognitive functions in postmenopausal women treated with Raloxifene. N. Engl. J. Med. 344(16):1207-1213.
Crossref

 
 

Yaffe K, Vittinghoff E, Ensrud KE, Johnson KC, Diem S, Hanes V, Grady D (2006). Effects of ultra-low dose transdermal estradiol on cognition and health-related quality of life. Arch. Neurol. 63:945-950.
Crossref

 
 

Yoon S, Jo SA, (2012). Mechanisms of amyloid β-peptide clearance: potential therapeutic targets for Alzheimer's disease. Biomol. Ther. 20(3):245-255.
Crossref

 
 

Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JCS (2002). Hormone replacement therapy and incidence of Alzheimer disease in older women the Cache County study. JAMA 288:2123-2129.
Crossref

 
 

Zemek F, Drtinova L, Nepovimova E, Sepsova V, Korabecny J, Klimes J Kuca K (2014). Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin. Drug Saf. 13(6):759-774.